InTrack Investment Management Inc purchased a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,544 shares of the pharmaceutical company’s stock, valued at approximately $645,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in VRTX. University of Texas Texas AM Investment Managment Co. purchased a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at about $25,000. Annapolis Financial Services LLC purchased a new stake in Vertex Pharmaceuticals in the first quarter valued at approximately $27,000. Arlington Trust Co LLC lifted its position in Vertex Pharmaceuticals by 97.1% during the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 33 shares during the last quarter. ICA Group Wealth Management LLC purchased a new position in Vertex Pharmaceuticals in the 4th quarter worth approximately $28,000. Finally, Fortitude Family Office LLC bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth $30,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.
Insider Activity
In related news, CMO Carmen Bozic sold 2,280 shares of the company’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $478.00, for a total value of $1,089,840.00. Following the sale, the chief marketing officer now directly owns 32,379 shares of the company’s stock, valued at $15,477,162. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, EVP Edward Morrow Atkinson III sold 7,288 shares of the business’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $478.00, for a total transaction of $3,483,664.00. Following the sale, the executive vice president now owns 15,972 shares of the company’s stock, valued at $7,634,616. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Carmen Bozic sold 2,280 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $478.00, for a total transaction of $1,089,840.00. Following the transaction, the chief marketing officer now directly owns 32,379 shares of the company’s stock, valued at approximately $15,477,162. The disclosure for this sale can be found here. Insiders sold a total of 28,366 shares of company stock worth $13,058,787 in the last quarter. 0.20% of the stock is owned by company insiders.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on VRTX
Vertex Pharmaceuticals Trading Up 0.5 %
Shares of VRTX traded up $2.53 during mid-day trading on Tuesday, hitting $473.78. 852,503 shares of the company’s stock traded hands, compared to its average volume of 1,238,103. The company has a quick ratio of 3.29, a current ratio of 3.50 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $122.26 billion, a P/E ratio of 30.77, a PEG ratio of 2.41 and a beta of 0.39. The business’s 50-day moving average price is $446.31 and its 200-day moving average price is $427.25. Vertex Pharmaceuticals Incorporated has a 1 year low of $335.82 and a 1 year high of $486.42.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.66 by $1.10. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The business had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.58 billion. During the same period in the previous year, the firm earned $2.67 EPS. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.22 EPS for the current fiscal year.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Read More
- Five stocks we like better than Vertex Pharmaceuticals
- Election Stocks: How Elections Affect the Stock Market
- RXO Shares Surge Following New Acquisition Deal
- What Are Dividend Contenders? Investing in Dividend Contenders
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- What is a Special Dividend?
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.